New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited.
Drug-induced toxic epidermal necrolysis (TEN), also known as Lyell's syndrome, is a life-threatening drug reaction characterized by extensive destruction of the epidermis and mucosal epithelia. The eyes are typically involved in TEN. At present, the disease has a high mortality rate. Conceptually, TEN and the Stevens-Johnson syndrome are closely related, although their severity and outcome are different. Distinguishing TEN from severe forms of erythema multiforme relies on consideration of aetiological, clinical and histological characteristics. The current understanding of the pathomechanism of TEN suggests that keratinocytes are key initiator cells. It is probable that the combined deleterious effects on keratinocytes of both the cytokine tumour necrosis factor (TNF)-alpha and oxidative stress induce a combination of apoptotic and necrotic events. As yet, there is no evidence indicating the superiority of monotherapy with corticosteroids, ciclosporin (cyclosporine) or intravenous immunoglobulins over supportive care only for patients with TEN. However, the current theory of TEN pathogenesis supports the administration of a combination of antiapoptotic/antinecrotic drugs (e.g. anti-TNF-alpha antibodies plus N-acetylcysteine) targeting different levels of the keratinocyte failure machinery.
Paquet
Philippe
P
Department of Dermatopathology, University Hospital of Liège, CHU Sart Tilman, Liège, Belgium. P.Paquet@chu.ulg.ac.be
Piérard
Gérald E
GE
D000111:Acetylcysteine / Q000633:toxicity; D017209:Apoptosis / Q000187:drug effects; D003875:Drug Eruptions; D004817:Epidermis / Q000473:pathology*; D004892:Erythema Multiforme / Q000209:etiology; D006801:Humans; D016756:Immunoglobulins, Intravenous; D015603:Keratinocytes / Q000187:drug effects* / Q000473:pathology; D008213:Lymphocyte Activation; D009336:Necrosis / Q000209:etiology; D012867:Skin / Q000187:drug effects / Q000473:pathology*; D013262:Stevens-Johnson Syndrome / Q000503:physiopathology / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000633:toxicity*
D016756:Immunoglobulins, Intravenous; D014409:Tumor Necrosis Factor-alpha; D000111:Acetylcysteine